An update on photodynamic therapy in age-related macular degeneration

Bibliography

• ARNOLD JJ, SARKS SH: Extracts from 'clinical evidence': age related macular degeneration. Br. Med. J. (2000) 321(7263):741–744.
   PubMedGoogle Scholar
• VINGERLING JR, KLAVER CCW, HOFMAN A, DE JONG PTVM: Epidemiology of age-related maculopathy. Epideiniol Rev (1995) 17:347–360.
   PubMed Web of Science ®Google Scholar
• Washington, DC: US Dept of Commerce, Bureau of the Census (1990). C9OSTF1C Online database.
   Google Scholar
• TAEUBER CM: Sixty-five plus in America: US Bureau of the Census: current population reports, special studies. Washington, DC: US Government Printing Office (1992):23–179.
   Google Scholar
• BIRD AC, BRESSLER NM, BRESSLER SB et al.: An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv. Ophthalinol (1995) 39(5):367–374.
   PubMed Web of Science ®Google Scholar
• •The new classification of AMD.
   Google Scholar
• KLEIN R, KLEIN BE, LINTON KL: Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology (1992) 99(6):933–943.
   PubMed Web of Science ®Google Scholar
• VINGERLING JR, DIELEMANS I, HOFMAN A et al.: The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology(1995) 102(2):205–210.
   PubMed Web of Science ®Google Scholar
• MITCHELL P, SMITH W, ATTEBO K,WANG JJ: Prevalence of age-relatedmaculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology (1995) 102(10):1450–1460.
   PubMed Web of Science ®Google Scholar
• SMITH W, ASSINK J, KLEIN R et al.: Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology (2001) 108(4):697–704.
   PubMed Web of Science ®Google Scholar
• MUNOZ B, WEST SK, RUBIN GS et al.: Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch. Ophthalinol (2000) 118(6):819–825.
   PubMed Web of Science ®Google Scholar
• SUNNESS JS, GONZALEZ-BARON J, APPLEGATE CA et al.: Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology (1999) 106(9):1768–1779.
   PubMed Web of Science ®Google Scholar
• Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age related macular degeneration and other causes. Retina (2002) 22(1):6–18.
   PubMedGoogle Scholar
• •A summary of guidelines for verteporfin in PDT, suggested by the Verteporfin Roundtable 2000 and 2001 participants.
   Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch. Ophthalinol (1997) 115(6):741–747.
   PubMedGoogle Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch. Ophthalinol (1993) 111:1189–1199.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch. Ophthalinol (1991) 109(8):1109–1114.
   Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch. Ophthalinol (1993) 111(9):1200–1209.
   Google Scholar
• MOISSEIEV J, ALHALEL A, MASURI R, TREISTER G: The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch. Ophthalinol (1995) 113(2):185–189.
   PubMedGoogle Scholar
• BRESSLER NM: Age related macular degeneration. New hope for a common problem comes from photodynamic therapy. Br. Med. J. (2000) 321(7274):1425–1427.
   Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Ophthalmology (1994) 112(4):500–509.
   Google Scholar
• SCHMIDT-ERFURTH U, HASAN T: Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv. Ophthalinol (2000) 45(3):195–214.
   PubMed Web of Science ®Google Scholar
• TAP STUDY GROUP: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch. Ophthalinol (1999) 117(10):1329–1345.
   Google Scholar
• ••One-year results of a landmark study reporting the beneficial effect of verteporfin in subfoveal neovascular AMD with a predominantly classic component.
   Google Scholar
• BRESSLER NM: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials — TAP report 2. Arch. Ophthalmol (2001) 119(2):198–207.
   PubMed Web of Science ®Google Scholar
• ••Two-year results of a landmark studyreporting the continuos beneficial effect of verteporfin in subfoveal neovascular AMD with a predominantly classic component.
   Google Scholar
• BRESSLER NM: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization — Verteporfin in Photodynamic Therapy report 2. Am. Ophthalmol (2001) 131(5):541–560.
   PubMedGoogle Scholar